Skip to content

oxLDL in Diabetes Mellitus Patients and Disease Periodontal

Disease Periodontal Influence on Markers of Cardiovascular in Diabetes Mellitus Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03198832
Enrollment
44
Registered
2017-06-26
Start date
2016-05-02
Completion date
2017-01-28
Last updated
2018-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus With Periodontal Disease

Keywords

Periodontal Disease, Type 2 Diabetes Mellitus, Z-scan, Atherosclerosis

Brief summary

Periodontal disease (PD) and diabetes mellitus type 2 (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters.

Detailed description

Periodontal disease (PD) and diabetes mellitus type 2 (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters. 44 patients will be divided into 2 groups: Diabetic Patients with Chronic Periodontitis (DM2DP) and Diabetic Patients without Chronic Periodontitis (DM2). The DM2DP group will receive periodontal debridement and DM2 group will be treated with supragingival scaling. Both groups receive board control every 3 months. At baseline, 3 and 6 months after treatment, will be held making the clinical periodontal parameters (plaque index, gingival index, probing depth, gingival recession relative clinical attachment level and Periodontal Inflamed Surface Area (PISA) index) and blood collection for assessment serum inflammatory markers (oxLDL, LDL, HDL, total cholesterol, triglyceride, Interleukin (IL) IL-6, IL-8, IL-10, Tumor Necrosis Factor (TNF-α) and CRP). Biochemical analyzes will be carried out by Z-scan technique. The data obtained before and after periodontal therapy will be analyzed using the Shapiro-Wilk test.

Interventions

PROCEDURENon-surgical periodontal treatment

Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .

Sponsors

LabviVale
CollaboratorOTHER
Universidade Estadual Paulista Júlio de Mesquita Filho
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Prospective double-blind controlled clinical study with a 6-month follow-up.

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* individuals older than 35 years with DM2 diagnosed for more than five years and HbA1c between 7% and 11%; * be diagnosed with generalized chronic periodontitis: present at least 6 sites with periodontal pocket and loss of insertion above 5mm and two more bags with loss of insertion above 6mm; * present at least 20 teeth; * agree to participate in the study and sign the informed consent form

Exclusion criteria

* patients with cardiovascular diseases, cancer, gastrointestinal disorders, skin diseases, pregnancy, lactation, smoking, arthritis, lupus or other diseases of inflammatory origin; * have undergone periodontal treatment in the last 12 months; * have made use of antioxidant supplements, anti-inflammatories, or antibiotics within the previous 3 months; * make use of medications that can alter the marking and concentration of oxLDL, for example, statins; * have changed the medication for glycemic control in the last 3 months; * present dental elements with pulpal or periapical inflammation.

Design outcomes

Primary

MeasureTime frameDescription
Probing depth changebaseline, 90 and 180 daysThe change in the probing depth will be measure in millimeters before and after the treatment.

Secondary

MeasureTime frameDescription
LDL, HDL, Total cholesterol, Triacylglycerolbaseline and 180 daysBlood concentration (g/ml) will be measured before and after periodontal therapy.
Plaque indexbaseline, 90 and 180 daysNumber of teeth affected before and after periodontal treatment
oxLDL concentration Changebaseline and 180 daysChange in concentration of oxLDL will be measured before and treatment.
Gingival Recessionbaseline, 90 and 180 daysEvaluated in millimeters before and after the treatment.
Clinical Attachment Levelbaseline, 90 and 180 daysEvaluated in millimeters before and after the treatment.
Gingival indexbaseline, 90 and 180 daysnumber of teeth affected before and after periodontal treatment

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026